Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia

Leukemia

Volumn 30, Issue 7, 2016, Pages 1599-1603

  Marke, R ^a   Havinga, J ^a   Cloos, J ^b   Demkes, M ^a   Poelmans, G ^c,d   Yuniati, L ^a   Van Ingen Schenau, D ^a   Sonneveld, E ^e   Waanders, E ^c   Pieters, R ^f   Kuiper, R P ^c   Hoogerbrugge, P M ^f   Kaspers, G J L ^b   Van Leeuwen, F N ^a   Scheijen, B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^f Department of Radiation Oncology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1BETA; PREDNISOLONE; TRANSCRIPTION FACTOR IKZF1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; IKAROS TRANSCRIPTION FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; LETTER; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WILD TYPE; ANIMAL; DRUG RESISTANCE; GENETICS; GENOTYPE; HUMAN; MUTANT MOUSE STRAIN;

ANIMALS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; GENOTYPE; GLUCOCORTICOIDS; HUMANS; IKAROS TRANSCRIPTION FACTOR; MICE; MICE, MUTANT STRAINS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE;

EID: 84954357729     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.359     Document Type: Letter

References (15)

1. Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood 2015; 125: 3977-3987.
2. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
3. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264.
4. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-3868.
5. Kaspers GJ, Pieters R, Van Zantwijk CH, VanWering ER, Van DerDoes-Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92: 259-266.
6. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
7. Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, et al. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer 2014; 61: 1779-1785.
8. Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res 2008; 101: 127-248.
9. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013-3022.
10. Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet 2015; 47: 607-614.
11. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 2013; 24: 766-776.
12. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
13. Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, Wen X, et al. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem 2014; 289: 20502-20515.
14. Ferreiros-Vidal I, Carroll T, Taylor B, Terry A, Liang Z, Bruno L, et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood 2013; 121: 1769-1782.
15. Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA, et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 2014; 15: 294-304.